Agent for the prevention and treatment of prostatic...

Details Agent for the prevention and treatment of prostatic... Agent for the prevention and treatment of prostatic...

A - Human Necessities

61

K

A61K 31/519 (2006.01) A61P 13/08 (2006.01)

Patent

CA 2647932

The present invention relates to an agent for preventing and treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH and a relaxant for relaxing urethral smooth muscle or prostatic smooth muscle comprising a pyrazolopyrimidinone compound as an effective ingredient. The agent in accordance with the present invention can provide nitric oxides by inhibiting the activity of PDE-5 that decomposes c-GMP, and the provided nitric oxides relax the urethral smooth muscle or the prostatic smooth muscle to lower the intraurethral pressure (IUP), thus treating BPH and LUTS associated with BPH. Furthermore, the time required for reaching a maximum blood concentration is shorter and the half-life is longer than the other PDE-5 inhibitors, thus reducing the frequency of administration. Moreover, the agent of the invention causing few side effects can be efficiently used as a safe drug.

Cette invention concerne un agent de prévention et de traitement de l'hyperplasie bénigne de la prostate (BPH) et de symptômes des voies urinaires inférieures (LUTS) associés à l'hyperplasie bénigne de la prostate (BPH) et un agent relaxant servant à relâcher le muscle lisse urétral ou le muscle lisse prostatique comprenant un composé pyrazolopyrimidinone comme principe actif. L'agent de cette invention peut produire des oxydes nitriques en inhibant l'activité de la PDE-5 qui décompose le c-GMP et les oxydes nitriques ainsi produits relâchent le muscle lisse urétral ou le muscle lisse prostatique dans le but d'abaisser la pression intra-urétrale (IUP), ce qui permet de traiter l'hyperplasie bénigne de la prostate (BPH) et les symptômes des voies urinaires inférieures (LUTS) qui lui sont associés. En outre, le temps qui lui est nécessaire pour atteindre une concentration sanguine maximum est réduit et sa demi-vie est plus longue que celle d'autres inhibiteurs de la PDE-5, ce qui réduit la fréquence d'administration. En outre, l'agent de cette invention ne causant que peu d'effets secondaires, il peut être efficacement utilisé sans danger comme médicament.

Affiliated with

Also associated with

Rating

Agent for the prevention and treatment of prostatic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agent for the prevention and treatment of prostatic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for the prevention and treatment of prostatic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2000197